碳纳米颗粒混悬液在早期宫颈癌前哨淋巴结活检中的作用:一项前瞻性研究
本研究前瞻性纳入356例Ia2-IIa2期宫颈癌患者,使用碳纳米颗粒混悬液(CNS)行前哨淋巴结活检(SLNB),随后行系统性盆腔淋巴结清扫。总体前哨淋巴结检出率为91.29%,肿瘤<20 mm患者检出率显著更高(97.75% vs 71.91%,P<0.001)。CNS引导的SLNB灵敏度为96.65%,假阴性率为4.35%,阴性预测值为99.29%;在肿瘤<20 mm亚组中灵敏度、阴性预测值均达100%,假阴性率为0%。
要点
- CNS用于早期宫颈癌SLNB总体检出率91.29%,肿瘤<20 mm者达97.75%。
- 总体灵敏度96.65%、假阴性率4.35%、阴性预测值99.29%。
- 肿瘤<20 mm亚组灵敏度、阴性预测值均100%,假阴性率0%。
核心结论
- CNS引导的SLNB在肿瘤较小的早期宫颈癌患者中具有良好的检出率、灵敏度和阴性预测值,安全、可行且相对有效,可指导精准手术治疗。
研究设计与样本
- 前瞻性研究,纳入356例Ia2-IIa2期宫颈癌患者,行CNS引导的SLNB后行系统性盆腔淋巴结清扫,淋巴结标本行常规组织病理学±病理超分期分析。
主要发现
- CNS在325例患者中识别出1456枚前哨淋巴结,总体检出率为91.29%。
- 肿瘤<20 mm患者检出率显著高于≥20 mm患者(97.75% vs 71.91%,P<0.001)。
- 2例患者出现假阴性结果;SLNB总体灵敏度96.65%,假阴性率4.35%,阴性预测值99.29%。
- 肿瘤<20 mm亚组(267例)灵敏度100%、阴性预测值100%、假阴性率0%。
- 检出率在病理类型、分级、分期、间质浸润深度、手术方式、绝经状态或既往化疗方面无显著差异(P>0.05)。
关键数值与推荐
- 总体前哨淋巴结检出率91.29%(325/356例)。
- 肿瘤<20 mm组检出率97.75% vs 肿瘤≥20 mm组71.91%(P<0.001)。
- 总体灵敏度96.65%,假阴性率4.35%,阴性预测值99.29%。
- 肿瘤<20 mm亚组(267例)灵敏度100%,阴性预测值100%,假阴性率0%。
临床怎么用
- 原文结论认为CNS引导的SLNB对肿瘤较小的早期宫颈癌患者安全、可行且相对有效,可指导精准手术治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the clinical diagnostic validity of carbon nanoparticle suspension (CNS) in sentinel lymph node biopsy (SLNB) for assessing lymphatic spread of early-stage cervical cancer. DESIGN: A prospective study. SETTING AND POPULATION: 356 cases. METHODS: We enrolled 356 stage Ia2-IIa2 cervical cancer patients to undergo SLNB using CNS, followed by systematic pelvic lymphadenectomy. All lymph node specimens were assessed using conventional histopathologic ± pathologic ultrastaging analyses. MAIN OUTCOME MEASURES: Sentinel lymph node detection rate (DR), clinical diagnostic validity and various related factors were analysed. RESULTS: CNS identified 1456 SLNs in 325 patients. The overall SLN DR was 91.29%. A significantly higher DR was found for patients with tumours <20 mm (97.75% versus 71.91%; P < 0.001). Two patients had false-negative results. SLNB with CNS had sensitivity of 96.65%, false-negative rate (FNR) of 4.35% and negative predictive value (NPV) of 99.29%. Importantly, sensitivity (100%), NPV (100%) and FNR (0%) were improved when testing the subgroup of patients with tumours <20 mm (267 cases). There were no observed differences in DR based on pathological type or grade, stage, depth of stromal invasion, surgical approach, menopausal status or prior treatment with chemotherapy (P > 0.05). CONCLUSIONS: Sentinel lymph node biopsy with CNS results in favourable DR, sensitivity and NPV for women with early-stage cervical cancer with small tumour sizes. SLNB with CNS is safe, feasible and relatively effective for guiding precise surgical treatment of early-stage cervical cancer. TWEETABLE ABSTRACT: Sentinel lymph node biopsy with carbon nanoparticle suspension is safe and feasible for early-stage cervical cancer.
引用
- Ya X, Qian W, Huiqing L, et al. Role of carbon nanoparticle suspension in sentinel lymph node biopsy for early-stage cervical cancer: a prospective study. BJOG. 2020. PMID: 32930483. doi:10.1111/1471-0528.16504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。